CSL posts FY profit above guidance
- {{x.value}}
{{ twilioFailed ? 'SMS Code Failed to Send…' : 'Enter verification code' }}
{{ completedStep1 ? 'Authentication & Security' : content.trialHeading.replace('{0}', user.FirstName) }}
{{ content.upgradeHeading.replace('{0}', user.FirstName) }}
The email address you entered is registered with InvestSMART
Please login to continue
We have sent you an email with the details of your registration.
Looks you are already a member. Please enter your password to proceed
{{ upgradeCTAText }}
Updating information
Please wait ...
Your membership to InvestSMART Group recently failed to renew.
Please make sure your payment details are up to date to continue your membership.
Having trouble renewing?
Please contact Member Services on support@investsmart.com.au or 1300 880 160
You've recently updated your payment details.
It may take a few minutes to update your subscription details, during this time you will not be able to view locked content.
If you are still having trouble viewing content after 10 minutes, try logging out of your account and logging back in.
Still having trouble viewing content?
Please contact Member Services on support@investsmart.com.au or 1300 880 160
Please click on the ACTIVATE button to activate your Intelligent Investor 15-day free trial
Please click on the ACTIVATE button to finalise your membership
Unsuccessful registration
Registration for this event is available only to Eureka Report members. View our membership page for more information.
Registration for this event is available only to Intelligent Investor members. View our membership page for more information.
- You are already registered for this event.
- This event is already full.
- Please select a quantity for at least one ticket.
- {{ i }}
Forgotten password
Please enter your email address below to request a new password
- Verify your email address by clicking on the link we sent to {{user.Email}}
- You now have free access, we look forward to helping you on your financial journey.
Blood products and vaccine supplier CSL Ltd is tipping profit growth of 10% for the current year despite economic headwinds weighing on trading conditions, after posting a bumper full-year net profit.
Investors were unimpressed by the news. At 1205 AEST shares in the company fell 2.76% to $65.93 against a benchmark index rise of 0.01%.
CSL's net profit rose 19% to $US1.21 billion ($1.33 billion) in the year to June on the previous corresponding period.
On a constant currency basis, net profit grew 21%, slightly ahead of the company's guidance of 20%.
Revenue rose to $US5.12 billion, from $US4.81 billion in the prior year.
Chief executive officer Paul Perreault said trading conditions would be "tempered by economic headwinds" and said earnings per share growth would eclipse expected profit growth of 10 per cent for the current year.
Brian McNamee retired this year after 25 years at the helm.
CSL will pay an unfranked final dividend of US 52 cents, pushing the total dividend to $US1.02, and 18% lift on the previous year, payable on 4 October.
Call 1300 880 160
Start a chat
Schedule a call
